The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

Mar. 19, 2018
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Merck Sharp & Dohme B. V., Haarlem, NL;

Sachin Mittal, Bridgewater, NJ (US);

Irina Kazakevich, Rockaway, NJ (US);

Himanshu Bhattacharjee, Princeton, NJ (US);

Peter Bakker, Zeist, NL;

Luke Schenck, Yardley, PA (US);

David J. Goldfarb, Highland Park, NJ (US);

Amitava Mitra, Princeton, NJ (US);

Donna Carroll, Garwood, NJ (US);

Nazia Khawaja, Morris Plains, NJ (US);

Inventors:

Sachin Mittal, Bridgewater, NJ (US);

Irina Kazakevich, Rockaway, NJ (US);

Himanshu Bhattacharjee, Princeton, NJ (US);

Peter Bakker, Zeist, NL;

Luke Schenck, Yardley, PA (US);

David J. Goldfarb, Highland Park, NJ (US);

Amitava Mitra, Princeton, NJ (US);

Donna Carroll, Garwood, NJ (US);

Nazia Khawaja, Morris Plains, NJ (US);

Assignees:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Merck Sharp & Dohme B.V., Haarlem, NL;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 9/10 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0019 (2013.01); A61K 31/4439 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 9/10 (2013.01); C07B 2200/13 (2013.01);
Abstract

The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).


Find Patent Forward Citations

Loading…